----item----
version: 1
id: {DCFBFE8F-6F00-404F-82AA-7BFA2BD351D5}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/14/GSK drug tops NHS primary care prescription spending
parent: {A8A43D63-6ACC-4DA4-B2AE-AFEB13F96A43}
name: GSK drug tops NHS primary care prescription spending
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: a8e431fa-8899-4245-b59e-51bc2c08cd9d

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 233

{3B33748A-17E9-4241-8447-989BB3484DFB}|{8B2376D2-D914-41D6-9402-D3CD38CABF23}|{38CC267C-7BFB-437D-BEA0-27DBA7B77873}|{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{1D288E18-BAFF-4498-B284-EF9BC8D32E30}|{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 55

 GSK drug tops NHS primary care prescription spending  
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 52

GSK drug tops NHS primary care prescription spending
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 7081

<p> GlaxoSmithKline's Seretide for asthma and chronic obstructive pulmonary disease (COPD) was the biggest selling branded primary care medicine in 2014 in England and Wales, according to research from Cogora, a healthcare media and marketing service company. </p> <p> Meanwhile, diabetes proved the most expensive drugs category for the National Health Service in England and Wales, which spent &pound;902m on such treatments, says Cogora's report <i>General Practice Prescribing Trends in England and Wales Review 2014.</i> </p> <p> The National Health Service in England and Wales spent &pound;9.16bn on primary care medicines in 2014, up from &pound;8.91bn in 2013. Nine of the top 10 selling brands in England and Wales were either respiratory corticosteroids or diabetes products, underscoring the cost of these disease areas to the NHS (see table below). The figures represent the cost to the NHS of the medicines, taking into account the basic price of a drug and excluding any discount, dispensing costs or fees. </p> <p> Nevertheless, the brands that showed the biggest growth were the asthma drug Fostair, which cost the NHS a total of &pound;31.5m, up by &pound;10.5m compared with 2013. The increase was down to the drug winning its second indication in April 2014 for COPD. </p> <p> <preform><script id="infogram_0__/qv2ewuL34CpskEIFD5YN" src="//e.infogr.am/js/embed.js?dd5" type="text/javascript"></script></preform></p> <p> After diabetes, respiratory corticosteroids were the second most costly category for the NHS at&pound;754.3m, followed by analgesics (&pound;586.2m), antiepileptics (&pound;498.6m) and oral nutrition products (&pound;380.4m). However, the mix could look different in 2015 as patent expiries hit Lantus and Seretide. The study also points out that Teva's DuoResp Spiromax, which won marketing authorization in April 2014 for asthma and COPD, will offer an alternative to Symbicort. </p> <p> <h2> Breakdown by treatment area </h2> <table> <tr> <td> <p> <b>Brand </b> </p> <p> &nbsp; </p> </td> <td> <p> <b>Treatment</b> </p> <p> &nbsp; </p> </td> <td> <p> <b>Manufacturer</b> </p> <p> &nbsp; </p> </td> <td> <p> <b>Cost in 2013 (&pound;m)</b> </p> <p> &nbsp; </p> </td> <td> <p> <b>Cost in 2014 (&pound;m)</b> </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> NovoRapid </p> <p> <p> &nbsp; </p> </td> <td> <p> diabetes </p> <p> &nbsp; </p> </td> <td> <p> Novo Nordisk </p> <p> &nbsp; </p> </td> <td> <p> 72.7 </p> <p> &nbsp; </p> </td> <td> <p> 75.1 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Lantus </p> <p> <p> &nbsp; </p> </td> <td> <p> diabetes </p> <p> &nbsp; </p> </td> <td> <p> Sanofi </p> <p> &nbsp; </p> </td> <td> <p> 71.6 </p> <p> &nbsp; </p> </td> <td> <p> 72.7 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> NovoMix </p> <p> <p> &nbsp; </p> </td> <td> <p> diabetes </p> <p> &nbsp; </p> </td> <td> <p> Novo Nordisk </p> <p> &nbsp; </p> </td> <td> <p> 58.7 </p> <p> &nbsp; </p> </td> <td> <p> 56.6 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Aviva reagent strips </p> <p> &nbsp; </p> </td> <td> <p> diabetes </p> <p> &nbsp; </p> </td> <td> <p> Roche </p> <p> <p> &nbsp; </p> </td> <td> <p> 42.1 </p> <p> &nbsp; </p> </td> <td> <p> 42.2 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Levemir </p> <p> <p> &nbsp; </p> </td> <td> <p> diabetes </p> <p> &nbsp; </p> </td> <td> <p> Novo Nordisk </p> <p> &nbsp; </p> </td> <td> <p> 41.6 </p> <p> &nbsp; </p> </td> <td> <p> 42.1 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Seretide </p> <p> <p> &nbsp; </p> </td> <td> <p> respiratory corticosteroid </p> <p> <p> &nbsp; </p> </td> <td> <p> GSK </p> <p> &nbsp; </p> </td> <td> <p> 182.3 </p> <p> &nbsp; </p> </td> <td> <p> 178.4 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Symbicort </p> <p> <p> &nbsp; </p> </td> <td> <p> Respiratory corticosteroid </p> <p> <p> &nbsp; </p> </td> <td> <p> AstraZeneca </p> <p> &nbsp; </p> </td> <td> <p> 81.9 </p> <p> &nbsp; </p> </td> <td> <p> 88.7 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Clenil Modulite </p> <p> <p> &nbsp; </p> </td> <td> <p> Respiratory corticosteroid </p> <p> <p> &nbsp; </p> </td> <td> <p> Chiesi </p> <p> &nbsp; </p> </td> <td> <p> 50.1 </p> <p> &nbsp; </p> </td> <td> <p> 51.4 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Fostair </p> <p> &nbsp; </p> </td> <td> <p> Respiratory corticosteroid </p> <p> <p> &nbsp; </p> </td> <td> <p> Chiesi </p> <p> &nbsp; </p> </td> <td> <p> 26.9 </p> <p> &nbsp; </p> </td> <td> <p> 31.5 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Qvar </p> <p> <p> &nbsp; </p> </td> <td> <p> Respiratory corticosteroid </p> <p> <p> &nbsp; </p> </td> <td> <p> Teva </p> <p> &nbsp; </p> </td> <td> <p> 21.0 </p> <p> &nbsp; </p> </td> <td> <p> 26.3 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> BuTrans </p> <p> &nbsp; </p> </td> <td> <p> analgesic </p> <p> &nbsp; </p> </td> <td> <p> Napp </p> <p> &nbsp; </p> </td> <td> <p> 15.9 </p> <p> &nbsp; </p> </td> <td> <p> 14.6 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> OxyContin </p> <p> &nbsp; </p> </td> <td> <p> analgesic </p> <p> &nbsp; </p> </td> <td> <p> Purdue </p> <p> &nbsp; </p> </td> <td> <p> 14.1 </p> <p> &nbsp; </p> </td> <td> <p> 14.3 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Durogesic </p> <p> <p> &nbsp; </p> </td> <td> <p> analgesic </p> <p> &nbsp; </p> </td> <td> <p> Janssen </p> <p> &nbsp; </p> </td> <td> <p> 10.9 </p> <p> &nbsp; </p> </td> <td> <p> 10.7 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Matrifen </p> <p> <p> &nbsp; </p> </td> <td> <p> analgesic </p> <p> &nbsp; </p> </td> <td> <p> Nycomed </p> <p> &nbsp; </p> </td> <td> <p> 10.4 </p> <p> &nbsp; </p> </td> <td> <p> 9.9 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Zapain </p> <p> <p> &nbsp; </p> </td> <td> <p> analgesic </p> <p> &nbsp; </p> </td> <td> <p> Amdipharm Mercury </p> <p> &nbsp; </p> </td> <td> <p> 7.9 </p> <p> &nbsp; </p> </td> <td> <p> 7.9 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Epilim </p> <p> <p> &nbsp; </p> </td> <td> <p> antiepileptic </p> <p> &nbsp; </p> </td> <td> <p> Sanofi </p> <p> &nbsp; </p> </td> <td> <p> 24.2 </p> <p> &nbsp; </p> </td> <td> <p> 24.5 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Keppra </p> <p> <p> &nbsp; </p> </td> <td> <p> antiepileptic </p> <p> &nbsp; </p> </td> <td> <p> UCB </p> <p> &nbsp; </p> </td> <td> <p> 17.7 </p> <p> &nbsp; </p> </td> <td> <p> 17.8 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Lamictal </p> <p> <p> &nbsp; </p> </td> <td> <p> antiepileptic </p> <p> &nbsp; </p> </td> <td> <p> GSK </p> <p> &nbsp; </p> </td> <td> <p> 10.6 </p> <p> &nbsp; </p> </td> <td> <p> 12.3 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Tegretol </p> <p> <p> &nbsp; </p> </td> <td> <p> antiepileptic </p> <p> &nbsp; </p> </td> <td> <p> Novartis </p> <p> &nbsp; </p> </td> <td> <p> 10.1 </p> <p> &nbsp; </p> </td> <td> <p> 10.2 </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Topamax </p> <p> <p> &nbsp; </p> </td> <td> <p> antiepileptic </p> <p> &nbsp; </p> </td> <td> <p> J&amp;J </p> <p> &nbsp; </p> </td> <td> <p> 3.0 </p> <p> &nbsp; </p> </td> <td> <p> 2.9 </p> <p> &nbsp; </p> </td> </tr> </table> <p> <i>Source: Cogora</i> </p> <p> 
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 264

<p> GlaxoSmithKline's Seretide for asthma and chronic obstructive pulmonary disease (COPD) was the biggest selling branded primary care medicine in 2014 in England and Wales, according to research from Cogora, a healthcare media and marketing service company. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 52

GSK drug tops NHS primary care prescription spending
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150414T050000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150414T050000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150414T050000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028473
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 55

 GSK drug tops NHS primary care prescription spending  
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{CB0FF25D-C5DE-4545-8944-A73FC9496B9B}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357865
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042331Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

a8e431fa-8899-4245-b59e-51bc2c08cd9d
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042331Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
